Company Overview of Twinstrand Therapeutics, Inc.
As of July 7, 2009, Twinstrand Therapeutics, Inc. was acquired by Cangene Corp. Twinstrand Therapeutics, Inc. operates as a biopharmaceutical company which engages in the discovery, development, and commercialization of biological drugs for the treatment of life-threatening diseases. Its products include TST10088, a recombinant protein-based prodrug for activation by matrix metalloproteinases associated with solid tumor forms of cancer. The company was formerly known as De Novo Enzyme Corporation and changed its name to Twinstrand Therapeutics, Inc. in January 2000. The company was founded in 1995 and is based in North Vancouver, Canada.
267 West Esplanade
North Vancouver, BC V7M 1A5
Founded in 1995
Key Executives for Twinstrand Therapeutics, Inc.
Twinstrand Therapeutics, Inc. does not have any Key Executives recorded.
Similar Private Companies By Industry
|2007262 Ontario, Inc.||Americas|
|2056273 Ontario, Inc.||Americas|
|AB BioPharma Inc.||Americas|
|AbCelex Technologies Inc.||Americas|
|AbCellera Biologics Inc.||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Twinstrand Therapeutics, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.